Redistribution of body fat induced by HIV protease inhibitors in patients with AIDS*

Redistribuição da gordura corporal induzida pelos inibidores de protease em pacientes com Aids*

Cristina Mansur¹ Rosyane Rena de Freitas² Felipe Torres Rabêlo³
Leonora Mansur⁴ Fábio Torres Rabêlo⁵ Frank César Monteiro Santiago⁶
Thaís de Oliveira⁷ Franceline Quintão Azevedo⁸

Abstract: Four patients with Human Immunodeficiency Virus Infection in treatment with protease inhibitors for an average of 8 months and 3 weeks are reported. Fat accumulation in the cervical-dorsal region (buffalo hump) and moon face, similar to that of Cushing’s Syndrome, are highlighted.

Keywords: HIV; Lipodystrophy; Protease inhibitors

INTRODUCTION

Over the last decade, treatment of the Acquired Immunodeficiency Syndrome (AIDS), thanks to the use of protease inhibitors and introduction of Haart (highly active anti-retroviral therapy), was able to recover patients considered to be terminal, restoration of the immune system, decrease in the number of deaths, increase in lifespan and improvement in the quality of life of patients bearing AIDS/HIV (Human Immunodeficiency Virus).¹

After two years of Haart introduction, a number of side effects became apparent. The first ones were fat accumulation in the abdominal region – making it round (Pot belly) –, enlargement of the dorsocervical region (Buffalo hump) and moon face, reminding Cushing’s syndrome.²⁻³ Besides centripetal fat accumulation, progressive alterations of cellular subcutaneous tissue in extremities have been noted, producing a pseudo-athletic appearance – with prominent muscles and vessels. Also observed were loss of peripheral cellular subcutaneous tissue (face, glutei,
upper and lower limbs) and metabolic alterations, such as dislipidemia, insulin resistance, lactic acido-
sis, hypogonadism and osteoporosis. This alteration
of body shape owing to a fat distribution abnormality
in individuals affected by HIV/AIDS is known as the
Fat Redistribution Syndrome (FRS).

CASE REPORTS

Case 1

Thirty-five-year-old female patient, who had
known to be an HIV bearer for eight years. She had
used AZT (zidovudine), DDI (didanosine), D4T (esta-
vudine) and 3TC (lamivudine). For one and a half
year she had been using 3TC, AZT and nelfinavir (pro-
tease inhibitor) and from six months before had
observed a centripetal fat accumulation, with enlarge-
ment of posterior cervical region (hump), lower por-
tion of the face, malar and mandibular regions and
intensive fat deposit in the dorsum (Figure 1).

Laboratorial tests: fasting blood glucose =
91mg/dl; total cholesterol = 216mg/dl; HDL =
38mg/dl e triglycerides = 152mg/dl.

Case 2

Forty-three-year-old male patient, knowingly
HIV bearer for nine years. He had already used AZT,
DDI and EFV (efavirenz). For two years he had been
using 3TC, D4T and ritonavir (protease inhibitor),
and since then he had been noticing progressive fat
loss in the malar region.

Laboratorial tests: fasting blood glucose =
115mg/dl; total cholesterol = 322mg/dl; HDL =
34mg e triglycerides = 931mg/dl.

Case 3

Forty-eight-year-old female patient (Figure 2),
bearer of HIV for 10 years and 11 months. She had
already used AZT, DDI, D4T and 3TC. For two years
and four months she had been using D4T, 3TC and
indinavir (protease inhibitor). After six months using
the latter scheme, she observed fat loss in malar
region and upper limbs (pseudo-athletic appear-
ance).

Laboratorial tests: fasting blood glucose =
85mg/dl; total cholesterol total = 214mg/dl; HDL =
33mg/dl e triglycerides = 221mg/dl.

Case 4

Forty-one-year-old male patient, infected by
HIV for eight years and seven months. He had already
used AZT, 3TC, D4T and DDI. Since January 2001, he
had used AZT, 3TC, ritonavir and indinavir, and soon
after beginning this scheme, noticed fat loss in the
malar region.

Laboratorial tests: fasting blood glucose =
124mg/dl; total cholesterol = 318mg/dl; HDL =
41mg/dl e triglycerides = 169mg/dl.

In all four patients, assays of post-nocturnal
plasmatic cortisol suppression with 1mg of dexameta-
sone were performed, discarding Cushing's syndro-
me.

DISCUSSION

HIV infection can be responsible for triggering
of a series of dermatological manifestations,4,5 and
body fat redistribution is increasingly observed in
these patients.6

The exact mechanism leading to the onset of
lipodystrophy is not known yet. Among the mentio-
ned, are: nucleoside analogues reverse transcriptase
inhibitors-induced mitochondrial toxicity; disregula-

Figure 1: Fat
deposit in
dorsum
(hump)

Figure 2: Bichat’s fat (malar fat) decrease
tion of TNF-alpha; protease inhibitor (PI)-related p450 citochrome inhibition; hypersteroidism (pseudo Cushing’s syndrome); local effects of HIV on cortisol production and alterations of other steroidal hormones. None of those is able to explain alone all aspects of this syndrome, which is probably multifactorial. 

Decrease in face fat is typical and described; however, fat accumulation in the dorsocervical region (hump) and moon face, reminding classic Cushing’s syndrome, are not so common. 

Lo and colaborators studied eight patients infected by HIV, with an average of 9.6 years of disease. Of these, four presented lipodystrophy between two and 18 months after beginning treatment with protease inhibitors. In the present patient set, average of onset was eight months and three weeks, corroborating data in the literature.

Prevalence rate of lipodystrophy ranges from five to 83% in patients using PI, with an average of 50%, and it can even occur in HIV/AIDS patients who are not using PI.

The syndrome has a larger incidence among females, and women present, proportionally, larger fat loss than men. Regional muscle loss was described in detail after Haart introduction.

FRS, glucose intolerance, hyperlipidemia and mitochondrial toxicity are the major issues and may persist after suspension of treatment (Coasting phenomenon).

With progression of lipodystrophy, several patients started presenting typical facies, characteristic of FRS. This brought the AIDS stigma back, leading many patients to treatment interruption.

It is necessary that specialists working with HIV/AIDS patients, and mainly dermatologists, identify these alterations and seek treatment options.

Abdominal treatment can be made with surgical removal by centripetal fat liposuccion. Fat absorption can be treated with growth hormone or aminoacid and vitamin supplements and supervised physical exercising, with satisfactory results. For the face, fat, collagen, hialuronic acid or metacrilate implantation can be used, with esthetical results and great improvement in patients’ life quality.

REFERENCES

5. Bonamigo RR, Nunes C, Arenzon S, Rietjens J.

Mail NAME:

Cristina Mansur
Rua Olegário Maciel 297/801 - Centro
36036-000 - Juiz de Fora - MG - Brazil
Tel.: +55 32 3215-4466 / Fax: +55 32 3217-4531
E-mail: cristina@mansur.com.br